Brief: AIDS Clinical Trial Presents Results From Phase 1 Study Of ModeX Trispecific Antibody For HIV Prevention, Treatment
05/03/2024 13:56
March 5 (Reuters) - ModeX Therapeutics:
* AIDS CLINICAL TRIAL GROUP PRESENTS RESULTS FROM PHASE 1
STUDY OF
MODEX TRISPECIFIC ANTIBODY FOR THE TREATMENT AND PREVENTION OF
HIV
* OPKO HEALTH INC: ANTIBODY WAS SAFE AND WELL-TOLERATED AT
ALL
DOSE LEVELS AND VIA BOTH INTRAVENOUS AND SUBCUTANEOUS
ADMINISTRATION
Source text for Eikon: ID:nGNX2Ss5Gb
Further company coverage: OPK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OPKO Health
See all newsOpko Health, Inc. Expected To Post A Loss Of 7 Cents A Share: Earnings Preview
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
US RESEARCH ROUNDUP-Bank7, Goldman Sachs, Morgan Stanley
Deals of the day-Mergers and acquisitions
US STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons